Key clinical point: Unintentional transduction of a single leukemic B cell induced resistance to CTL019 (tisagenlecleucel) therapy.
Major finding: A patient with B-cell acute lymphoblastic leukemia (B-ALL) had frank relapse 9 months after a CTL019 infusion, with more than 90% bone marrow infiltration of chimeric antigen receptor–transduced B-cell leukemia cells.
Study details: A case study of a 20-year-old male with B-ALL undergoing CTL019 therapy.
Disclosures: Study funding was provided by Bristol-Myers Squibb, Novartis, the National Institutes of Health, and others. Dr. Ruella and several of his colleagues work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research and are inventors of intellectual property licensed by the University of Pennsylvania to Novartis.
Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9.
This Week's Must Reads
Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30
Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919
DOACs perform well in real-world AF study, ESC CONGRESS 2018
T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51
Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308
Must Reads in Leukemia, Myelodysplasia, Transplantation
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
New Choosing Wisely Guidance on BMT Released , Biol Blood Marrow Transplant; ePub 2018 Jan 19; Bhella, et al
Second Primary Malignancies in Patients with MM, Biol Blood Marrow Transplant; ePub 2018 Jan 12; Sahebi, et al
Progression to MM in Patients with MGUS Assessed, N Engl J Med; 2018 Jan 18; Kyle, Larson, et al
These 2 Markers May Impact MGUS Progression to MM , Leuk Lymphoma; ePub 2018 Jan 18; Vallet, et al